Furthermore, COX16, COX17, and SLC16A2 may represent attractive therapeutic targets for HPV+ HNSCC that warrant further exploration, especially considering that treatment with specific inhibitors may phenocopy the effects of low expression of these metabolic genes. This evidence concerns the gene COX16 and head and neck squamous cell carcinoma.